Patient
SITE002-0069
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE002 (USA) (Dr. Nolan)
consented 2025-11-24
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-12 (study day 165); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 153); relationship: NOT RELATED
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 126); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 85); relationship: RELATED
Grade 1 Asthenia — outcome: UNKNOWN; onset 2022-08-10 (study day 71); relationship: RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 48); relationship: NOT RELATED
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 28); relationship: NOT RELATED
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 6); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.